Abstract
Gold nanoparticles stabilized with polyethylene glycol were used to study their cytotoxicity and antiviral activity against HIV-1 in the laboratory. The HeLa-CD4-LTR-B-gal cell line was used with gold nanoparticles to determine the cell viability using luminescent assay. The 50% cytotoxicity concentration, IC50 of gold nanoparticles was found to be 1.12 ± 0.05 mg/ml. M-tropic, T-tropic, dual tropic and resistant isolates were inhibited by gold nanoparticles and their inhibition concentration ranged from 0.05 to 0.12 mg/ml. The mechanism of gold nanoparticles against HIV-1 is not clear but it inhibits the HIV-1 fusion. In this study, the gold nanoparticles were used to analyze their mode of antiviral activity and the experimental results showed that they inhibit the viral entry by binding with gp120 and prevent CD4 attachment. These properties of gold nanoparticles make them as an effective antiviral inhibitor.
Keywords: Gold nanoparticle, cytotoxic, broad - spectrum, immune system, viral inhibition, HIV-1, AIDS, antiviral, inhibitor, concentration
Current HIV Research
Title:Gold Nanoparticles as an HIV Entry Inhibitor
Volume: 10 Issue: 8
Author(s): S. Vijayakumar and S. Ganesan
Affiliation:
Keywords: Gold nanoparticle, cytotoxic, broad - spectrum, immune system, viral inhibition, HIV-1, AIDS, antiviral, inhibitor, concentration
Abstract: Gold nanoparticles stabilized with polyethylene glycol were used to study their cytotoxicity and antiviral activity against HIV-1 in the laboratory. The HeLa-CD4-LTR-B-gal cell line was used with gold nanoparticles to determine the cell viability using luminescent assay. The 50% cytotoxicity concentration, IC50 of gold nanoparticles was found to be 1.12 ± 0.05 mg/ml. M-tropic, T-tropic, dual tropic and resistant isolates were inhibited by gold nanoparticles and their inhibition concentration ranged from 0.05 to 0.12 mg/ml. The mechanism of gold nanoparticles against HIV-1 is not clear but it inhibits the HIV-1 fusion. In this study, the gold nanoparticles were used to analyze their mode of antiviral activity and the experimental results showed that they inhibit the viral entry by binding with gp120 and prevent CD4 attachment. These properties of gold nanoparticles make them as an effective antiviral inhibitor.
Export Options
About this article
Cite this article as:
Vijayakumar S. and Ganesan S., Gold Nanoparticles as an HIV Entry Inhibitor, Current HIV Research 2012; 10 (8) . https://dx.doi.org/10.2174/157016212803901383
DOI https://dx.doi.org/10.2174/157016212803901383 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Mini-Reviews in Medicinal Chemistry Managing Sleep Disturbance in Bipolar Disorder
Current Psychiatry Reviews Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery Discovery of Novel Regulatory Peptides by Reverse Pharmacology: Spotlight on Chemerin and the RF-amide Peptides Metastin and QRFP
Current Protein & Peptide Science Parallel Roles for Dopamine in Pathological Gambling and Psychostimulant Addiction
Current Drug Abuse Reviews Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
Current Medicinal Chemistry Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Current Neuropharmacology Are We There Yet? The Clinical Potential of Intranasal Oxytocin in Psychiatry
Current Psychiatry Reviews Plant Substances as Antiviral Agents: An Update (1997-2001)
Current Organic Chemistry Current Status of Tyrosine Hydroxylase in Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science State of the Art: Psychotherapeutic Interventions Targeting the Psychological Factors Involved in IBD
Current Drug Targets Oligonucleotide-Directed Mutagenesis and Targeted Gene Correction: A Mechanistic Point of View
Current Molecular Medicine Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Drugs for AIDS
Mini-Reviews in Medicinal Chemistry The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design